These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32038762)

  • 1. New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis.
    Psomadakis CE; Han G
    J Clin Aesthet Dermatol; 2019 Dec; 12(12):28-34. PubMed ID: 32038762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
    Woo TE; Kuzel P
    Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating crisaborole as a treatment option for atopic dermatitis.
    Ramachandran V; Cline A; Feldman SR; Strowd LC
    Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
    Cheape AC; Murrell DF
    Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of boron in dermatology.
    Jackson DG; Cardwell LA; Oussedik E; Feldman SR
    J Dermatolog Treat; 2020 Feb; 31(1):2-12. PubMed ID: 28789577
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of psoriasis with crisaborole.
    Lee EB; Lebwohl MG; Wu JJ
    J Dermatolog Treat; 2019 Mar; 30(2):156-157. PubMed ID: 29812961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
    Crowley EL; Gooderham MJ
    Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
    Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
    J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Treatment Options in Atopic Dermatitis: Topical Therapies.
    Nygaard U; Deleuran M; Vestergaard C
    Dermatology; 2017; 233(5):333-343. PubMed ID: 29216643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Atopic Dermatitis and Topical Therapies.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(3):227-236. PubMed ID: 28300440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse.
    Cork MJ; Britton J; Butler L; Young S; Murphy R; Keohane SG
    Br J Dermatol; 2003 Sep; 149(3):582-9. PubMed ID: 14510993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis.
    Frantz T; Wright EG; Balogh EA; Cline A; Adler-Neal AL; Feldman SR
    Children (Basel); 2019 Nov; 6(11):. PubMed ID: 31694234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
    Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
    Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies in pediatric dermatology.
    Lofgren S; Krol A
    Curr Opin Pediatr; 2011 Aug; 23(4):399-402. PubMed ID: 21602678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
    Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
    J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging trends in the treatment of atopic dermatitis.
    Gelbard CM; Hebert AA
    Patient Prefer Adherence; 2008 Feb; 2():387-92. PubMed ID: 19920986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
    Simpson EL; Paller AS; Boguniewicz M; Eichenfield LF; Feldman SR; Silverberg JI; Chamlin SL; Zane LT
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):605-619. PubMed ID: 30345457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of topical immunomodulators for the treatment of atopic dermatitis.
    Abramovits W; Boguniewicz M; Paller AS; Whitaker-Worth DL; Prendergast MM; Tokar M; Tong KB
    Pharmacoeconomics; 2005; 23(6):543-66. PubMed ID: 15960552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.